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Abstract
Background: Plexiform angiomyxoid myofibroblastic tumor (PAMT) is a very rare mesenchymal tumor of the
stomach. Here we report a case of pathologically confirmed PAMT with an unique cyst formation.
Case presentation: A 55-year-old male with a 10-year history of a gastric subepithelial tumor underwent
computed tomography (CT) and magnetic resonance imaging (MRI). Two cysts were observed in the tumor, and
the cyst wall showed moderately high intensity on T2-weighted images compared with the gastric wall. On
dynamic study, the cyst wall showed a gradual enhancement pattern, and prominent enhancement was observed
in the delayed phase. Laparoscopic partial gastric resection was performed, and a pathological diagnosis of PAMT
was rendered.
Conclusion: We present a rare case of gastric PAMT, which was uniquely presented as cysts. One of the cysts in
the tumor had an epithelial wall lining, which had never been reported before in gastric mesenchymal tumor, in
addition to partial glandular structure. We reviewed our case, focusing on radiologic-pathologic correlation, and
suggested hypothesis of cyst formation. According to our findings, PAMT with cyst formation would be included of
differential diagnosis of gastric subepithelial tumors.
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Background
Plexiform angiomyxoid myofibroblastic tumor (PAMT) is
a rare mesenchymal tumor of the stomach that was first
described by Takahashi et al. in 2007 [1]. The incidence of
PAMT is estimated to be less than 1 in 150 compared
with gastric gastrointestinal stromal tumor (GIST) [2],
and only 34 cases of PAMT have been reported in the
English language literature, with scant data pertaining to
computed tomography (CT) and magnetic resonance im-
aging (MRI) findings [3–19]. Here, we describe a case of
PAMT with unique cystic formation, focusing on the im-
aging findings and radiological-pathological correlation.
Case presentation
A 55-year-old male with a 10-year history of a gastric
subepithelial tumor followed-up by upper gastrointes-
tinal endoscopy at other clinic visited our institution
with a complaint of tumor enlargement. The patient did
not experience any discomfort, and his laboratory test
results were all normal.
Upper gastrointestinal endoscopy showed a subepithe-
lial mass, 2 cm in diameter, at the posterior wall of the
gastric angle. Small dimples were observed at the apex
of the tumor. A biopsy was performed, and viscous li-
quid was ejected from the tumor. The biopsy results
were insufficient for a diagnosis.
On non-enhanced CT (Aquilion One; Toshiba,
Tochigi, Japan), 19 mm subepithelial tumor showed low
attenuation. Dynamic enhanced CT was performed after
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injection of 100 mL iomeprol 350 (Bracco-Eisai, Tokyo,
Japan) at a rate of 3.3 mL/s. The arterial phase was ob-
tained at 30 s, and the delayed phase was obtained at
90 s. The tumor showed two cysts and a thin cyst wall
with moderate enhancement in the arterial phase and
strong enhancement in the delayed phase (Fig. 1). On
follow-up CT performed 4 months later for preoperative
evaluation, the whole tumor slightly enlarged to 23 mm,
and one of the cysts was enlarged (Fig. 1 short arrow),
whereas the other showed shrinkage (Fig. 1 long arrow).
No lymphadenopathy was seen.
On MRI (MAGNETOM Skyra 3 T; Siemens, Erlangen,
Germany) performed 4.5 months later from the initial
CT scan, 2 cm subepithelial tumor composed by two
cysts was also observed. The cyst showed high intensity,
and the cyst wall showed moderately high intensity,
compared with the gastric wall, on T2-weighted images.
On T1-weighted images, the cyst showed low intensity,
and the cyst wall showed iso-intensity to the gastric wall.
On diffusion-weighted imaging (image not shown), no
apparent diffusion restriction was seen, and the tumor
showed iso-intensity to the gastric wall. Dynamic en-
hanced MRI was performed after injection of 0.2 mL/kg
body weight gadopentetate dimeglumine (Magnevist;
Japan Schering, Osaka, Japan) at a rate of 2 mL/s. The
arterial, portal and delayed phases were obtained at 20,
50 and 120 s, respectively. As with the dynamic
enhanced CT findings, the cyst wall showed a gradual
enhancement pattern, with strong enhancement seen in
the delayed phase (Fig. 2).
The differential diagnosis of the gastric subepithelial
tumor included schwannoma, GIST, ectopic pancreas,
duplication cyst with cyst wall inflammation, and adeno-
carcinoma arising from a duplication cyst. Although the
patient had a long history of a tumor, laparoscopic
partial gastric resection was performed, because the
possibility of malignancy could not be ruled out.
Macroscopically, a 17-mm yellowish nodular lesion
was present from the lamina propria mucosa to the sub-
mucosa. Two cysts were observed within the tumor, one
of which showed an epithelial wall lining. The tumor
also showed a partial glandular structure. Histologically,
the tumor cells were bland and spindle shaped, without
significant nuclear atypia or mitosis, accompanied by
abundant myxoid matrix. In the myxoid matrix, numerous
small, thin-walled vessels were observed. Immunohisto-
chemically, the tumor cells were positive for alpha-smooth
muscle actin and negative for c-KIT, CD10, CD34, desmin,
S-100 protein, and epithelial membrane antigen. Based on
the above results, the tumor was diagnosed as PAMT
(Fig. 3). MIB-1 labeling index was less than 1%. Due to
this pathological result, no further follow up is performed.
Discussion
PAMT of the stomach is a rare mesenchymal tumor that
typically shows a multinodular plexiform growth pattern.
PAMT is composed of myofibroblastic spindle cells, sep-
arated by intercellular myxoid or fibromyxoid matrix,
with rich arborizing capillaries [1]. Immunohistochemi-
cally, PAMT is positive for vimentin and muscle actin
[10]. c-KIT, CD34, and S-100 protein is negative in
PAMT, which are usually positive in GIST, GIST and
solitary fibrous tumor, and schwannoma and neuro-
fibroma, respectively. Typically, PAMT is positive for
alpha-smooth muscle actin, and focal immunoreactivity
for desmin and caldesmon is occasionally seen [10].
PAMT may also contain tumor cells with fibroblastic
or smooth muscle characteristics [2, 4, 16] and therefore
is sometimes reported as “plexiform fibromyxoma” or
“plexiform angiomyxoid tumor” [2, 4]. However, Sing
et al. suggested that PAMT could be distinguished from
plexiform fibromyxoma according to its immunohisto-
chemical and clinicopathological features [9]. Those au-
thors claimed that vascular invasion and extragastric
extension are usually seen in plexiform fibromyxoma,
with no immunoreactivity against caldesmon or desmin;
in contrast, PAMT does not show vascular invasion, and
focal reactivity for desmin and caldesmon is seen occa-
sionally. Takahashi et al., who discovered PAMT, sug-
gested that plexiform fibromyxoma is a fibroblastic trait
Fig. 1 Dynamic enhanced computed tomography (CT) (a, non-enhanced CT; b, arterial phase; c, delayed phase) revealed a gastric subepithelial tumor
at the posterior wall of the gastric angle. Long arrow indicates the cyst shrank, and short arrow indicate the cyst enlarged on the follow-up CT
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of PAMT [10]. Although the precise nomenclature re-
mains controversial, “plexiform fibromyxoma” was
classified as a mesenchymal tumor of the stomach in
the 2010 World Health Organization classification of
digestive system tumors [20]. Because the majority of
tumor cells show a predominantly myofibroblastic
nature, we believe that PAMT is the appropriate diag-
nostic term reflecting the histogenesis and histology
of this tumor. Furthermore, we believe that this is
supported by the fact that more cases have been re-
ported as PAMT, rather than as plexiform fibromyx-
oma, even after 2010.
Fig. 2 Magnetic resonance imaging (MRI) (a, T1-weighted image; b, fat suppressed T2-weighted image; c, arterial phase; d, delayed phase) of the
tumor showed cysts with a thin wall. The wall exhibited hyperintensity on T2-weighted images and a gradual enhancement pattern, which
reflects the myxoid nature of the tumor
Fig. 3 Pathological findings of the tumor. a, macroscopic findings: the tumor is located mainly in the submucosa, and two cysts are observed
within the tumor; b–d, microscopic examination (hematoxylin and eosin staining on three different power fields) showing a partial epithelial
lining in the cyst wall and some glandular structures within the tumor. Spindle tumor cells are seen in the rich myxoid stroma. The tumor cells
are positive for alpha-smooth muscle actin (e) and negative for c-KIT (f)
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To date, including the present case, 35 cases of PAMT
have been reported in the English language literature. Of
these cases, the patient age ranged from 7–75 years
(median = 43 years), and no sex difference was evident
(M:F = 17:18). Tumor size varied from 1.5 to 15 cm
(mean 5.2 cm), and the majority of the PAMTs occurred
in the gastric antrum and pylorus. However, PAMTs can
occur anywhere in the stomach, including the fundus and
body [7, 12, 15]. Since mucosal ulceration was seen in ap-
proximately half of the cases [1, 2, 4–6, 11, 12, 15, 17],
PAMT may cause hematemesis, gastrointestinal bleeding,
and anemia, although incidentally found PAMTs are not
rare [9, 12, 15, 16]. Although vascular invasion was seen
in some of the cases reported by Miettinen et al. [2], the
prognosis of PAMT seems to be benign tumor, since no
recurrence or metastasis has been reported to date.
There are only a few studies reporting CT and MRI
findings of PAMT (summarized in Table 1). Among the
cases in which dynamic studies were performed, one
showed a gradual enhancement pattern, and three
showed a gradual enhancement pattern plus prominent
enhancement in the delayed phase, which is compatible
with the myxoid nature of the tumor. In the case who
demonstrated a gradual enhancement pattern, there was
only relatively weak enhancement in the delayed phase
[18]. This might be because the tumor was negative for
alpha-smooth muscle actin, showing mainly the fibro-
blastic traits of PAMT. A case reported by Kang et al.
also showed strong enhancement, although the exact
timing of performing CT scanning was not specified
[12]. Only one case, reported by Sing et al., showed poor
enhancement [9]. The CT image shown in their paper
was apparently taking during the arterial phase, which
may have been too early to demonstrate enhancement of
this myxoid tumor. Including our case, there are only
two reports of PAMT that include MRI findings [18].
Both cases showed hyperintensity on T2-weighted im-
ages and no apparent diffusion restriction. Along with
the findings of the dynamic study, these MRI findings
reflect the myxoid nature of this tumor. Furthermore,
we assume that prominent enhancement in the delayed
phase is also due to rich small vessels in the myxoid
matrix. Although these are characteristic imaging find-
ings, it may be difficult to distinguish PAMT from other
myxoid tumors, such as myxoid variants of GIST.
Cyst formation appears to be rare in PAMT, and only
three cases have been reported previously. In two of
those cases, the tumor was continuous and showed a
sac-like structure that had a hemorrhagic inner wall with
multiple perforations [8, 14]. In the other case,
hemorrhage, necrosis, and cystic degeneration were seen
in a tumor 14 cm in size [10]. Unlike these former cases,
unique cyst formations were observed within the tumor
in our case. Of the two cysts, the shrunken cyst did not
show an epithelial wall lining, while the enlarged cyst did.
We speculate that both cysts had an epithelial lining, but
that the lining in the shrunken cyst was exfoliated. The
cause of these cysts is unclear, and two explanations can
be offered: the first is that the PAMT grew until it sur-
rounded the heterotopic epithelial cells, and a cyst formed
from the mucus secreted from these cells. This hypothesis
may be supported by the fact that the tumor showed a
partial glandular structure. The other explanation is that
the PAMT occurred near these cysts and then grew until
it surrounded them. Our case is the first report of a gastric
subepithelial mesenchymal tumor containing a cyst with
an epithelial lining; therefore, more data are required to
confirm the true nature of these cysts.
Conclusion
In conclusion, we reported a case of PAMT, a rare sube-
pithelial mesenchymal tumor of the stomach. MRI and dy-
namic study findings reflected the myxoid nature of this
tumor well. A cyst with an epithelial wall lining was ob-
served in the gastric subepithelial mesenchymal tumor for
the first time. We believe radiologist should be aware that
PAMT should be included to differential diagnosis of cys-
tic subepithelial tumor with myxoid imaging feature.





Unenhanced CT T1WI (MRI) T2WI (MRI) DWI (MRI) Dynamic CT or MRI Reference
1 35/F 4 antrum NA NA NA NA EC(poorly enhancing) [9]
2 47/M 3 mid body NA NA NA NA EC(prominent enhancing) [12]
3 38/F 3.5 upper body NA NA NA NA PE [15]
4 27/F 4.6 antrum inhomogeneous
low
NA NA NA PE [17]
5 60/M 2.0 antrum NA iso high not high gradual enhancement [18]
Present
case
55/M 1.7 angle low iso high iso PE
NA indicates that data was not available, EC indicates that only enhanced, CT was performed and parenthesis shows description in original case reports, PE
represents gradual enhancement pattern plus prominent enhancement in delayed phase
For T1WI, T2WI and DWI, tumor signal is compared to that of the gastric wall
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